Navigation Links
InterMune to Present at Canaccord Adams Conference
Date:8/7/2008

BRISBANE, Calif., Aug. 7 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Daniel G. Welch, Chairman, CEO and President of InterMune, will present at the Canaccord Adams 28th Annual Global Growth Conference in Boston on August 13, 2008 at 1:00 p.m. EDT.

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at http://www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
2. InterMune to Present at BMO Healthcare Conference
3. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
4. InterMune to Present at Jefferies Healthcare Conference
5. InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences
6. InterMune to Present at Citigroup Healthcare Conference
7. InterMune to Present at Bank of America Health Care Conference
8. InterMune to Present at Deutsche Bank Health Care Conference
9. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
10. Evotec Expands Collaboration With InterMune
11. InterMune to Present at the SIGnificant Options in Healthcare Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)..., CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Oncoly...ics" or the "Company") today announced updated res...(R) in patients with sarcomas metastatic to the lu...nective Tissue Oncology Society Meeting held in Mi...poster presentation, entitled "A Phase II Study of...
(Date:11/5/2009)... TRANSPORTATION -- Gone hybrid . . . , Fuel e...iles are now posted at the www.fueleconomy.gov w...oped and maintains for the U.S. Department of Ener...ine of the top 10 vehicles on the best fuel econom...us (51 MPG city; 48 highway). "This list proves th...
(Date:11/5/2009)..., PARSIPPANY, N.J., Nov. 5 DSM Ph...made a manufacturing alliance with Galenix, Saint ...red commercial scale manufacturing partner for Gal...DSM and Galenix will collaborate on business devel...ivery technologies, based on the strength of Galen...
(Date:11/5/2009)..., Conference Call on Thursday, November 5, 2009 a...NCOUVER Nov. 5 /PRNewswire-FirstCall/ - OncoGenex ...") (NASDAQ: OGXI ) today reported unaudited finan... ended September 30, 2009 and reviewed the Company... The following consolidated results reflect the op...
Breaking Biology Technology:Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 3DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8
...fairs,Group (TSPAG), an accomplished, bi-partisan ...ss the country, has changed its name to Troutman,S...ack record of success,with agribusiness, appropria...on issues among others., "The name change reflect... in 2002 and its expanding business and geographic...
..., Massachusetts, HARRISBURG, Pa., July 23 Pennsy...echnology business sector have,made it the number ...ilities magazine study, Governor Edward G. Rendell...p Pennsylvania number one in,biotech," Governor Re...anking. "The commonwealth,s support for the entire...
... for Regaining Compliance - - NASDAQ Hearing Pan... Additional 180 Days to Regain Compliance...pital Market Initial Listing Requirements Ot...IN, Calif., July 23 Peregrine,Pharmaceuticals, In...ved a,Staff Determination letter from the Nasdaq S...
Other Biology Technology:Leading Lobbying Firm Celebrates Growth and New Name: Troutman Sanders Strategies 2Pennsylvania Governor Rendell Says State Number 1 in New Biotechnology Study 2Pennsylvania Governor Rendell Says State Number 1 in New Biotechnology Study 3Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule 2Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule 3Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule 4
(Date:11/4/2009)... Calif., Nov. 4 GenVault Corporati...dy, M.D., Ph.D., has joined its Board of Directors...of the Salk Institute, is an acclaimed physician-s...the Salk Institute, Dr. Brody served as president ...f the National Academy of Engineering and the Inst...
(Date:11/3/2009)...ON, FL (November 4, 2009) For more than 25 years,...onch ( Strombus gigas ) have been unsuccessfulunti...eeding techniques to produce beaded (nucleated) an...have been developed by scientists from Florida Atl...titute (HBOI). With less than two years of researc...
(Date:11/3/2009)...ED, FLLaser labeling of fruit and vegetables is a ...bon dioxide laser beam is used to label, or "etch"...eed for common sticker-type labels. The technology...and vegetables and is being used in New Zealand, A...een approved in Asia, South Africa, Central and So...
Breaking Biology News(10 mins):Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 2Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 3Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 2Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 3Laser etching safe alternative for labeling grapefruit 2Ongoing Study Shows That Endovascular Therapy is Associated With High Cure Rate for Childhood Eye Cancer 52979 1Ongoing Study Shows That Endovascular Therapy is Associated With High Cure Rate for Childhood Eye Cancer 52979 2Ongoing Study Shows That Endovascular Therapy is Associated With High Cure Rate for Childhood Eye Cancer 52979 3Ongoing Study Shows That Endovascular Therapy is Associated With High Cure Rate for Childhood Eye Cancer 52979 4Photos 3A Compete Releases Top Insurance and Physician Web Sites for June 2009 52976 1Photos 3A Compete Releases Top Insurance and Physician Web Sites for June 2009 52976 2Photos 3A Compete Releases Top Insurance and Physician Web Sites for June 2009 52976 3Photos 3A Compete Releases Top Insurance and Physician Web Sites for June 2009 52976 4Established Medical Sub Component Manufacturer Achieves ISO 13485 Certification 52972 1Established Medical Sub Component Manufacturer Achieves ISO 13485 Certification 52972 2Established Medical Sub Component Manufacturer Achieves ISO 13485 Certification 52972 3
...online edition of Nature Structural and Molecular...e of Medicine describe a technique for looking mo...e a gene, DNA, being read into a message, mRNA. T...ss by which genes are switched on inappropriately,... detailed look into processes that until now were ...
...rs from two of the nation,s largest industries me...g with academicians from the University of Houston...lood. , Much like moving oil through a pipeline...h systems need clean, well-functioning pipes (or b...function with incredible efficiency. Both industr...
...tates that are at the highest risk of sustaining d...to the dangers posed by rising temperatures, accor...of climate change that has already significantly a... has already had widespread ecological and hydrolo...he United States will experience at least as much ...
Other Biology News:Einstein researchers develop technique to count messages made by single genes 2Using the other guy's toolkit: Similarities of pumping blood, oil examined 2Most US organizations not adapting to climate change 2Most US organizations not adapting to climate change 3
...ac™ Concentrators set the standard for sampl...SC210A SpeedVac with large chamber uses a combinat...ultiple samples in a single run. , SC210A comes eq... for long lasting chemical compatibility , ...
...d Bio for vacuum concentrator/centrifugal evapora...lecular biology and biochemistry for rapid and saf...tems can be expanded with pumps, different of cold... sample loss by transfer), ensuring solvent recove...
Explorer Software Suite. Complete software and PC for datalogging, programming, control and monitoring for Explorer SpeedVac System [please inquire for latest PC configuration] from Thermo Scientific
MBS Thermal Cycler 1 Block Laptop Kit from Thermo Scientific
Biology Products: